Pulmonary Embolism in Acquired Hemophilia A: A Rare Complication With Factor VIII Inhibitor Bypassing Activity Therapy
2020; Cureus, Inc.; Linguagem: Inglês
10.7759/cureus.9152
ISSN2168-8184
AutoresHafiz Muhammad Aslam, Timothy Chong, Joseph Park, Ted Nicolosi, Rehan Shah,
Tópico(s)Blood Coagulation and Thrombosis Mechanisms
ResumoAcquired hemophilia A (AHA) is an uncommon complication caused by autoantibodies against Factor VIII. The main concern with these patients is hemorrhage, which is often treated with Factor VIII inhibitor bypassing activity (FEIBA). On rare occasions, treatment with FEIBA can result in thromboembolism, a potentially fatal complication. This unfortunate situation occurred in our patient, a 64-year-old female who was treated with FEIBA after being diagnosed with AHA. After initiating FEIBA, she developed clinical signs and symptoms of pulmonary embolism, which was ultimately responsible for her acute death. While pulmonary embolism may be a rare complication of FEIBA treatment, clinicians should be aware of its possibility, especially as the complete safety profile for this treatment is not well known.
Referência(s)